IATI Biomed 2016: Personalized cancer drug co in AbbVie collaborationMay. 23, 2016
Founded only a few months ago, Israeli startup Hide and Seq, which deals in personalized cancer treatment, has signed an agreement with AbbVie and Sheba Medical Center (Tel Hashomer). The three entities will utilize Hide and Seq's expertise in finding patients that will have the best responses to the new drug treatments being developed by AbbVie.
Hide and Seq will present its activity at the IATI Biomed 2016 conference on May 24-26 in Tel Aviv. The company will participate in the part of the conference that involves personalized medicine, and in a startup competition taking place as part of the conference.
Hide and Seq cofounder and CTO Dr. Alona Zilberberg explains her company's business like this: "We detected a genomic difference between various patients with ovarian cancer, which shows which patients it is worthwhile treating with a drug named Paclitaxel, which will not help other patients. Today, most patients receive this chemotherapeutic treatment, which lengthens life expectancy in some cases, but is ineffective in other cases, and causes unnecessary side effects and costs, when the time could be used for other treatments."